A multi-institutional acute gastrointestinal toxicity analysis of anal cancer patients treated with concurrent intensity-modulated radiation therapy (IMRT) and chemotherapy

Radiotherapy and Oncology

Volumn 93, Issue 2, 2009, Pages 298-301

  Devisetty, Kiran ^a   Mell, Loren K ^b   Salama, Joseph K ^a,c   Schomas, David A ^d   Miller, Robert C ^d   Jani, Ashesh B ^e   Roeske, John C ^f   Aydogan, Bulent ^a,c   Chmura, Steven J ^a,c  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^d MAYO CLINIC   (United States)

^e EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Anal cancer; Chemoradiotherapy; Dosimetric analysis; Gastrointestinal toxicity; IMRT

Indexed keywords

ATROPINE PLUS DIPHENOXYLATE; CISPLATIN; FLUOROURACIL; LOPERAMIDE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ADULT; AGED; ANUS CANCER; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CORRELATION ANALYSIS; DOSIMETRY; FEMALE; FOLLOW UP; GASTROINTESTINAL TOXICITY; HUMAN; INTENSITY MODULATED RADIATION THERAPY; INTESTINAL DYSMOTILITY; MALE; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RADIATION DOSE; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANUS NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; FLUOROURACIL; GASTROINTESTINAL TRACT; HUMANS; MALE; MIDDLE AGED; MITOMYCIN; RADIOTHERAPY, INTENSITY-MODULATED;

EID: 70350494286     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2009.07.006     Document Type: Article

References (27)

1. Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research. Lancet 1996;348:1049-54.
2. Bartelink H., Roelofsen F., Eschwege F., et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol 15 (1997) 2040-2049
3. Flam M., John M., Pajak T.F., et al. Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. J Clin Oncol 14 (1996) 2527-2539
4. Ajani J.A., Winter K.A., Gunderson L.L., et al. Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. JAMA 299 (2008) 1914-1921
5. Salama J.K., Mell L.K., Schomas D.A., et al. Concurrent chemotherapy and intensity-modulated radiation therapy for anal canal cancer patients: a multicenter experience. J Clin Oncol 25 (2007) 4581-4586
6. Saarilahti K., Arponen P., Vaalavirta L., and Tenhunen M. The effect of intensity-modulated radiotherapy and high dose rate brachytherapy on acute and late radiotherapy-related adverse events following chemoradiotherapy of anal cancer. Radiother Oncol 87 (2008) 383-390
7. Milano M.T., Jani A.B., Farrey K.J., Rash C., Heimann R., and Chmura S.J. Intensity-modulated radiation therapy (IMRT) in the treatment of anal cancer: toxicity and clinical outcome. Int J Radiat Oncol Biol Phys 63 (2005) 354-361
8. Menkarios C., Azria D., Laliberte B., et al. Optimal organ-sparing intensity-modulated radiation therapy (IMRT) regimen for the treatment of locally advanced anal canal carcinoma: a comparison of conventional, IMRT plans. Radiat Oncol 2 (2007) 41
9. Hsu A, Hara W, Pawlicki T, Bazan J, Koong A, Goodman K. IMRT in the treatment of anal cancer: a dosimetric comparison of conventional 3D, IMRT, and IMRT with integrated boost. Int J Radiat Oncol Biol Phys 2006;66:S674.
10. Kachnic L., Tsai H.K., Willins J., et al. Dose-painted intensity modulated radiation therapy for anal cancer: dosimetric comparison and acute toxicity. Int J Radiat Oncol Biol Phys 66 (2006) S280
11. Mell L.K., Schomas D.A., Salama J.K., et al. Association between bone marrow dosimetric parameters and acute hematologic toxicity in anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 70 (2008) 1431-1437
12. Roeske J.C., Bonta D., Mell L.K., Lujan A.E., and Mundt A.J. A dosimetric analysis of acute gastrointestinal toxicity in women receiving intensity-modulated whole-pelvic radiation therapy. Radiother Oncol 69 (2003) 201-207
13. Mell LK, Roeske JC, Mehta N, Mundt AJ. Gynecologic cancer: overview. In: Mundt AJ, Roeske JC, editors. Intensity modulated radiation therapy: a clinical perspective. Hamilton, Ontario: BC Decker Inc.; 2005. p. 492-505.
14. Common Terminology Criteria for Adverse Events, version 3.0.
15. Radiation Therapy Oncology Group Acute Radiation Morbidity Scoring Criteria.
16. Glantz, SA, Slinker, BK. Primer of applied regression and analysis of variance. New York: McGraw-Hill, Health Professions Division; 1990. p. 488-93.
17. Gallagher M.J., Brereton H.D., Rostock R.A., et al. A prospective study of treatment techniques to minimize the volume of pelvic small bowel with reduction of acute and late effects associated with pelvic irradiation. Int J Radiat Oncol Biol Phys 12 (1986) 1565-1573
18. Tho L.M., Glegg M., Paterson J., et al. Acute small bowel toxicity and preoperative chemoradiotherapy for rectal cancer: investigating dose-volume relationships and role for inverse planning. Int J Radiat Oncol Biol Phys 66 (2006) 505-513
19. Baglan K.L., Frazier R.C., Yan D., Huang R.R., Martinez A.A., and Robertson J.M. The dose-volume relationship of acute small bowel toxicity from concurrent 5-FU-based chemotherapy and radiation therapy for rectal cancer. Int J Radiat Oncol Biol Phys 52 (2002) 176-183
20. Robertson J.M., Lockman D., Yan D., and Wallace M. The dose-volume relationship of small bowel irradiation and acute grade 3 diarrhea during chemoradiotherapy for rectal cancer. Int J Radiat Oncol Biol Phys 70 (2008) 413-418
21. Minsky B.D., Conti J.A., Huang Y., and Knopf K. Relationship of acute gastrointestinal toxicity and the volume of irradiated small bowel in patients receiving combined modality therapy for rectal cancer. J Clin Oncol 13 (1995) 1409-1416
22. Letschert J.G., Lebesque J.V., Aleman B.M., et al. The volume effect in radiation-related late small bowel complications: results of a clinical study of the EORTC Radiotherapy Cooperative Group in patients treated for rectal carcinoma. Radiother Oncol 32 (1994) 116-123
23. Herbert S.H., Curran Jr. W.J., Solin L.J., Stafford P.M., Lanciano R.M., and Hanks G.E. Decreasing gastrointestinal morbidity with the use of small bowel contrast during treatment planning for pelvic irradiation. Int J Radiat Oncol Biol Phys 20 (1991) 835-842
24. Lutgens L.C., Deutz N.E., Gueulette J., et al. Citrulline: a physiologic marker enabling quantitation and monitoring of epithelial radiation-induced small bowel damage. Int J Radiat Oncol Biol Phys 57 (2003) 1067-1074
25. Lutgens L.C., Deutz N., Granzier-Peeters M., et al. Plasma citrulline concentration: a surrogate end point for radiation-induced mucosal atrophy of the small bowel. A feasibility study in 23 patients. Int J Radiat Oncol Biol Phys 60 (2004) 275-285
26. Lutgens L., and Lambin P. Biomarkers for radiation-induced small bowel epithelial damage: an emerging role for plasma Citrulline. World J Gastroenterol 13 (2007) 3033-3042
27. Graf R., Wust P., Hildebrandt B., et al. Impact of overall treatment time on local control of anal cancer treated with radiochemotherapy. Oncology 65 (2003) 14-22